Science 2002; 296: 539-541. 14. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular response and thrombosis in canine arteries. Circulation 2001; 104: 820-825. 15. Shinmura K, Tang XL, Wang Y et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase ischemic preconditioning in conscious rabbits. Proc Nat Acad Sci USA 2000, 97:10197-10202. 16. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal. Arthritis Rheum., 2003; 48: 12-20. 17. Marcus AJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation. N Engl J Med., 2002; 347: 1025-1026. 18. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific online pharmacy viagra, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-430. 19. Konstam MA, Weir AR. Current persective on the cardiovascular effects of coxibs. Clev Clin J Med 2002; (suppl 1): SI-1947-SI-52. 20. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum (Arthritis Care & Res) 2002; 47:349-355. 21. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase-2 inhibitor - celecoxib. ACR 66th Annual Scientific Meeting, New Orleans, 2002; 485. 22. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory druds (ibuprofen, diclofenac and nabumeton). Am Cardiol. 2002; 89: 204-209. 23. Singh GS, Garnier P, Hwang E. et al. Meloxicam does not increase the risk of cardiovascular adverse events compared to other NSAIDs: results from the IMPROVE trial, a multi-center, randomized parallel-group, open label study of 1,309 patients in a managed case setting. EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0259 (abst). 24. Lander SA, Wallace DJ, Weisman MH Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11: 340-347 25. Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts J, van Laar MAFJ. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002; 41: 458-461. 26. Van Hecken A., Schwarts JL, Depre M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin Pharm 2000, 40: 1109-1120. 27. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162; 1111-1115. 28. Solomon DH, Glynn RJ, Levone R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction Arch Intern Med 2002; 162: 1099-1104. 29.
